Luc-Matthieu Fornecker

6PUBLICATIONS
44CO-AUTHORS
Tumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 18, 2023
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.

Guillaume Cartron, Emmanuel Bachy, Hervé Tilly

|Feb 17, 2023
Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T-cell lymphoma: A French retrospective study.

Sammara Chaubard, Amira Marouf, David Lavergne

|Jul 22, 2022
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.

Luc-Matthieu Fornecker, Julien Lazarovici, Igor Aurer

|Jun 22, 2021
Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011).

Isabelle Demeestere, Judith Racape, Julie Dechene

|Apr 17, 2021
Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study.

Marion Lam, Valérie Touitou, Sylvain Choquet

|Apr 09, 2021
Temporal multiomic modeling reveals a B-cell receptor proliferative program in chronic lymphocytic leukemia.

Cedric Schleiss, Raphael Carapito, Luc-Matthieu Fornecker

Pageof 1

Frequent Collaborators

3 joint publications

David Sibon

3 joint publications

René-Olivier Casasnovas

2 joint publications

Roch Houot

2 joint publications

Franck Morschhauser